Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study.

Background: Guidelines advise 50 % and 25 % dose reduction of the therapeutic nadroparin dose (86 IU/kg) in patients with eGFR 15-29 and 30-60 ml/min respectively. For monitoring, peak anti-Xa levels are suggested. Data lack whether this results in therapeutic anti-Xa levels or in anti-Xa levels that are comparable to those of patients without renal impairment.
Aims: To determine dose ranges in patients with renal impairment that result in therapeutic anti-Xa levels and to determine the percentage of the 86 IU/kg dose that results in anti-Xa levels normally occurring in patients without renal impairment.
Methods: A retrospective cohort study was conducted in five hospitals. Patients ≥18 years of age, with an eGFR ≥ 15 ml/min were included. The first correctly sampled peak (i.e. 3-5 h after ≥ third administration, regardless of dose per patient) was included. Simulated prediction models were developed using multiple linear regression.
Results: 770 patients were included. eGFR and hospital affected the association between dose and anti-Xa level. The doses for peak anti-Xa levels of 0.75 IU/ml differed substantially between hospitals and ranged from 55 to 91, 65-359 and 68-168 IU/kg in eGFR 15-29, 30-60 and > 60 ml/min/1.73m ² , respectively. In eGFR 15-29 and 30-60 ml/min/1.73m ² , doses of 75 % and 91 % of 86 IU/kg respectively, were needed for anti-Xa levels normally occurring in patients with eGFR > 60 ml/min.
Conclusion: We advise against anti-Xa based dose-adjustments as long as anti-Xa assays between laboratories are not harmonized and an anti-Xa target range is not validated. A better approach might be to target levels similar to eGFR > 60 ml/min/1.73m ² , which are achieved by smaller dose reductions.
Competing Interests: Declaration of competing interest K. Meijer reports speaker fees from Alexion, Bayer and CSL Behring, participation in trial steering committee for Bayer, consulting fees from Uniqure, participation in data monitoring, and endpoint adjudication committee for Octapharma, all outside the submitted work; The other authors report no competing interest associated with the work reported in the manuscript.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)